Els Van Valckenborgh

4.9k total citations · 1 hit paper
77 papers, 2.9k citations indexed

About

Els Van Valckenborgh is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Els Van Valckenborgh has authored 77 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Molecular Biology, 44 papers in Hematology and 29 papers in Oncology. Recurrent topics in Els Van Valckenborgh's work include Multiple Myeloma Research and Treatments (44 papers), Chemokine receptors and signaling (15 papers) and Protein Degradation and Inhibitors (15 papers). Els Van Valckenborgh is often cited by papers focused on Multiple Myeloma Research and Treatments (44 papers), Chemokine receptors and signaling (15 papers) and Protein Degradation and Inhibitors (15 papers). Els Van Valckenborgh collaborates with scholars based in Belgium, United States and France. Els Van Valckenborgh's co-authors include Karin Vanderkerken, Eline Menu, Elke De Bruyne, Ivan Van Riet, Hendrik De Raeve, Ken Maes, Ben Van Camp, Jinheng Wang, Kim De Veirman and Miguel Lemaire and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Els Van Valckenborgh

73 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bone marrow stromal cell–derived exosomes as communicators in drug resistance in multiple myeloma cells

2014 366 citations Miguel Lemaire, Elke De Bruyne et al. Blood profile →

Peers

Els Van Valckenborgh

HEMAT

ONCOL

IMMUN

Ben Van Camp Belgium

Salomon Manier France

Patricia Maiso United States

Claudia S. Huettner United States

Monica Iurlaro Italy

Matthias Kotzsch Germany

Robert L. Cohen United States

Mark B. Meads United States

Maria Teresa Masucci Italy

Nerbil Kilic Germany

Ben Van Camp Belgium

Els Van Valckenborgh

1.2k ×0.7

1.3k ×1.0

HEMAT

1.2k ×1.1

ONCOL

351 ×0.5

265 ×0.4

IMMUN

Citations per year, relative to Els Van Valckenborgh Els Van Valckenborgh (= 1×) peers Ben Van Camp

Countries citing papers authored by Els Van Valckenborgh

Since Specialization

Citations

This map shows the geographic impact of Els Van Valckenborgh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Els Van Valckenborgh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Els Van Valckenborgh more than expected).

Fields of papers citing papers by Els Van Valckenborgh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Els Van Valckenborgh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Els Van Valckenborgh. The network helps show where Els Van Valckenborgh may publish in the future.

Co-authorship network of co-authors of Els Van Valckenborgh

This figure shows the co-authorship network connecting the top 25 collaborators of Els Van Valckenborgh. A scholar is included among the top collaborators of Els Van Valckenborgh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Els Van Valckenborgh. Els Van Valckenborgh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aftimos, Philippe, Kevin Punie, Lore Decoster, et al.. (2023). 181P GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative. Annals of Oncology. 34. S253–S254.

McCrary, J. Matt, Els Van Valckenborgh, Jeroen van Rooij, et al.. (2023). 1725P Genetic counselling for cancer in EU member states: Review and foundation for consensus recommendations. Annals of Oncology. 34. S939–S939.

Delnord, Marie, Els Van Valckenborgh, Aline Hébrant, et al.. (2021). Precision cancer medicine: What has translated into clinical use in Belgium?. Seminars in Cancer Biology. 84. 255–262. 8 indexed citations

Vanneste, Kevin, Wim Coucke, Aline Hébrant, et al.. (2020). NGS for (Hemato-) Oncology in Belgium: Evaluation of Laboratory Performance and Feasibility of a National External Quality Assessment Program. Cancers. 12(11). 3180–3180. 4 indexed citations

Veirman, Kim De, Eline Menu, Ken Maes, et al.. (2018). Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway. Cancer Letters. 442. 233–241. 48 indexed citations

Veirman, Kim De, Nathan De Beule, Ken Maes, et al.. (2017). Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunology Research. 5(10). 839–846. 44 indexed citations

Veirman, Kim De, Els Van Valckenborgh, Qods Lahmar, et al.. (2014). Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies. Frontiers in Oncology. 4. 349–349. 88 indexed citations

Hu, Jinsong, Els Van Valckenborgh, Dehui Xu, et al.. (2013). Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro. Molecular Cancer Therapeutics. 12(9). 1763–1773. 49 indexed citations

Lemaire, Miguel, Prasoon Agarwal, Eline Menu, et al.. (2012). The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin. Clinical Cancer Research. 18(8). 2230–2239. 13 indexed citations

10.

Xu, Dehui, Jinsong Hu, Elke De Bruyne, et al.. (2012). Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochemical and Biophysical Research Communications. 428(4). 518–524. 42 indexed citations

11.

Maes, Ken, Miguel Lemaire, Jordan Gauthier, et al.. (2012). The DNA Methyltransferase Inhibitor Decitabine Induces DNA Damage, Cell Cycle Arrest and Apoptosis in Multiple Myeloma. Blood. 120(21). 1833–1833. 3 indexed citations

12.

Lemaire, Miguel, Sarah Deleu, Elke De Bruyne, et al.. (2011). The Microenvironment and Molecular Biology of the Multiple Myeloma Tumor. Advances in cancer research. 110. 19–42. 60 indexed citations

13.

Menu, Eline, Els Van Valckenborgh, Ben Van Camp, & Karin Vanderkerken. (2009). The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Archives of Physiology and Biochemistry. 115(2). 49–57. 32 indexed citations

14.

Menu, Eline, Helena Jernberg‐Wiklund, Hendrik De Raeve, et al.. (2007). Targeting the IGF‐1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival. International Journal of Cancer. 121(8). 1857–1861. 54 indexed citations

15.

Bruyne, Elke De, Thomas Levin Andersen, Hendrik De Raeve, et al.. (2006). Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients. Leukemia. 20(10). 1870–1879. 19 indexed citations

16.

Menu, Eline, Evy De Leenheer, Hendrik De Raeve, et al.. (2006). Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clinical & Experimental Metastasis. 23(5-6). 291–300. 90 indexed citations

17.

Valckenborgh, Els Van, et al.. (2005). Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model. Leukemia. 19(9). 1628–1633. 26 indexed citations

18.

Valckenborgh, Els Van, Peter I. Croucher, Hendrik De Raeve, et al.. (2004). Multifunctional role of matrix metalloproteinases in multiple myeloma: study in the 5T2mm mouse model.. VUBIR (Vrije Universiteit Brussel). 1 indexed citations

19.

Vanderkerken, Karin, Isabelle Vande Broek, Décio L. Eizirik, et al.. (2002). Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clinical & Experimental Metastasis. 19(1). 87–90. 45 indexed citations

20.

Vanderkerken, Karin, Els Van Valckenborgh, Marleen Bâkkus, et al.. (2000). Bone marrow microenvironmental-induced upregulation of MMP-9 activity in murine multiple myeloma cells. Clinical & Experimental Metastasis. 17(9). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact